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INTRODUCTION
Cancer remains a leading cause of death worldwide. In the US alone, annual incidence exceeds one million with more than 500,000 deaths. There is still an unmet need for novel highly effective and selective antitumor agents with low toxicity that do not readily elicit tumor resistance. An attractive target is ribonucleotide reductase (RNR), the only enzyme responsible for the de novo conversion of ribonucleoside diphosphate (NDP) to deoxyribonucleoside diphosphate (dNDP). (1) (2) (3) RNR is the key regulator of intracellular dNTP supply.(4) Maintenance of a balanced dNTP pool is a fundamental cellular function because the consequences of imbalance in the substrates for DNA synthesis and repair include mutagenesis and cell death. RNR expression and activity is therefore tightly regulated both in the cell cycle and at the DNA damage checkpoints. (3, 5) Targeted inhibition of RNR depletes dNTPs, and could lead to aberrant replication forks, S-phase checkpoint activation and cell cycle arrest. (5) Human RNR is composed of α subunits (RRM1) that contain the catalytic site and two binding sites for enzyme regulators, and β subunits (RRM2) with a binuclear iron co-factor that generates the stable tyrosyl radical necessary for catalysis.(6) Reduction of NDP to dNDP at the RRM1 catalytic center requires formation of the active quaternary structure, and transfer of radicals generated in the RRM2 subunit (~ 45 kDa) to the RRM1 subunit (~85 kDa) via a proposed 35 Å proton-coupled electron transfer (PCET) pathway. (7) Until recently the active quaternary structure of RNR holoenzyme as well as the PCET pathway was unclear. (8) However, the C-terminal tail of RRM2 is involved in the RRM1-RRM2 interface formation and radical transfer. (9) Normal cells with a low proliferative status express very low levels of RNR whereas neoplastic cells overexpress RNR to manufacture dNTP pools to support DNA synthesis and proliferation. While both RRM1 and RRM2 are required for RNR holoenzyme activity, each subunit has differing significance in cancer. Overexpression of RRM2 promotes transformation and tumorigenic potential via its cooperation with several activated oncogenes. (10) Conversely, overexpression of RRM1 suppresses malignant potential in vivo. (11) In cancer cells in vitro, increased expression of RRM2 increased drug-resistance and invasive potential, whereas RRM2 suppression reversed drug resistance and decreased proliferation. (12) (13) (14) (15) Clearly, RNR is directly involved in tumor growth, metastasis, and drug resistance. Therefore RNR, especially the RRM2 subunit, is an important target for anticancer agents. Strategies for RNR inhibition include free radical quenching (radical scavenger), dinuclear iron center disruption (iron chelator), interfering with catalysis and regulation at the RRM1 subunit by nucleoside analogs, perturbation of critical interactions between subunits, and inhibition of RRM1 or RRM2 expression. (3, 16, 17) There is clinical experience for three RNR inhibitors; hydroxyurea (HU), 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®), and GTI2040. HU has a 30 year history as a cancer therapeutic agent, and blocks DNA synthesis by reducing the RNR free radical. (18) However, resistance to HU is readily developed, limiting its usefulness. 3-AP, which is in human phase II clinical testing relies on iron chelation. Toxicities reported from the phase I trial were hypoxia, respiratory distress, and methemoglobulinemia, apparently due to iron chelation in the patients' red blood cells (RBC). (19) We observed that 3-AP was associated with iron chelation in inhibition of the alternate β subunit, p53R2. (20) The RRM2 antisense oligonucleotide, GTI2040, showed strong antitumor activity in animal models, however, it had no significant benefit in human phase II trials. (21, 22) In summary, the current RNR inhibitors have drawbacks including short half-life, enzyme recovery, and strong iron chelation. Effective and specific RNR inhibitors for the clinic have yet to be developed. We present here the development using structure-and mechanism-based approaches of a novel potent RNR inhibitor, COH29, which binds a novel pocket located at the RRM1 and RRM2 interface. COH29 could overcome the known drawbacks of the existing RNR inhibitors and is a potentially attractive antineoplastic agent. 
MATERIALS & METHODS

Virtual-screening workflow
A working database prepared from known RRM2 inhibitors combined with 1441 compounds from the cleaned Developmental Therapeutics Program (DTP) NCI Diversity Set free-for-public access database of compounds representing the NCI library of 250,253 compounds (NCI2000) was virtually screened against pocket 5 using SYBYL FlexX docking tool (Tripos-Certara, Inc.). DTP compounds that successfully docked into pocket 5 were ranked using an embedded consensus docking score (25) and compared to known hRRM2 inhibitors. The 80 compounds with the highest docking scores and binding energies superior to the known inhibitors were compiled into a hit list, and obtained from NCI for in vitro validation. Details of the procedure have been described previously. (26) In vitro Activity and screening Assay
The activities of recombinant hRRM2/hRRM1 were measured using a modified [ 3 H] CDP reduction assay (5) as previously described.(23) Measurement of RNR activity in cell lysates was as previously described. (27, 28) Hit compounds (100 µM) were initially screened using an in vitro RNR activity.
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Surface Plasmon Resonance Analysis
The surface plasmon resonance measurements were performed using Biacore T1000 equipped with hRRM2 immobilized onto research grade CM4 sensor chips. See the Supplemental Data for further details.
Real-time Cell Proliferation, Viability Assays, and Cell Cycle Analysis
The human epidermal carcinoma cell line KB was purchased from American Type Culture Collection (ATCC). Cells were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% Penicillin-Streptomycin (GibcoBRL). Development of the Gem-resistant clone (KBGem) and hydroxyurea resistant clone (KBHU) have been described previously.(12, 13) Human normal dermal fibroblasts (NHDF) and umbilical vein endothelial cells (HUVEC) were purchased from Clonetics, Lonza, San Diego, CA. Cultures were maintained at 37°C in a humidified atmosphere of 5% CO 2 .
Cell proliferation was monitored using a W200 real-time cell electronic sensing analyzer (RT-CES) 16X workstation (Acea Biosciences) (30) . Each well of the RT-CES plate was seeded with 2,500 cells.
Twenty-four hours later, the index and curve of cell proliferation of quadruplicate samples were monitored and plotted every half hour for 120 hours. Viability was assessed by MTS assays performed according to manufacturer's instructions (CellTiter 96 AQueous Assay reagent; Promega) on 10 replicates 
RESULTS
Protein structure description
To design a novel class of specific RRM2 inhibitors, we used the only human RRM2 structure then available, PDB ID 2UW2. The main structural motif of hRRM2 is eight bundled long helices (αA to αH)
Research. with connecting shorter helices (α1 to α3) and loops. The unusual α-barrel structure has three layers of helices hosting a diiron-radical cofactor and a structurally flexible C-terminal tail (C-loop) (Fig. 1A) invisible by current biophysical techniques, but known to be at the RRM1-RRM2 interface and involved in the radical transfer (9) . The exact active quaternary structure of the mammalian class Ia RNR holoenzyme is still unknown. The model of the R1R2 holoenzyme complex built based on the E. coli subunit structures, where the upper layer αH and the C-loop are close to the RRM1-RRM2 interface, remains the most accepted (31, 32) .
Ligand binding pocket identification
We identified five ligand binding pockets by mapping the hRRM2 structure. We discounted four pockets for either being too close to the iron center or too shallow. The largest cavity (pocket 5) had the greatest potential for RNR inhibition and was enclosed by 32 amino acid residues from the hRRM2 αE, αF, and αH helices, and the C-loop and is sufficiently far from the iron center to avoid ligand-induced iron chelation (Fig. 1A) .
We tested these five pockets against known RRM2 ligands using the SYBYL FlexX built-in docking site search algorithm, which identifies the most fitted sites by mapping the entire protein (25) We virtually screened the structure diversified NCI Diversity Set (NCI2000) for novel RRM2 inhibitors, then tested a hit list of 80 compounds using an in vitro RNR activity assay. Ten compounds inhibited the activity of the recombinant human RRM2/RRM1 complex by over 50%, and four by over 80%. Of these, compound NSC#659390 had the most favorable solubility and toxicity, and we used this formula to synthesize compound COH3 for further study.
COH3 is an aromatically substituted thiazole compound consisting of ring systems A and B flanking a linking group (Fig. 1B) . We explored the pharmacophore features by structure-activity relationship (SAR) analysis of 20 COH3 analogues.(33) RNR inhibition was abolished by removing the 3, 4-dihydroxyl group from the phenyl ring, replacing it by 3, 5-dihydroxyl, or adding one more OH group, suggesting the dihydroxyl functional group at ortho position is mandatory for inhibition. Deleting the linking group, or replacing the binding group with bulkier or hydrophobic groups decreased RNR inhibition. Adding 3, 4-OH groups on the benzene (B) ring binding group (COH20, Fig. 1D ) increased inhibition of recombinant RNR compared to COH3. We concluded that inhibition of RNR by the compound was likely due to radical quenching by the 3, 4-dihydroxyl group, which is proposed as the pharmacophore. The pharmacophore model that we generated for lead compound optimization is shown in Fig. S1 .
Ligand binding mode by computer modeling
Pocket 5 is v-shaped with polar and charged residues at the surface opening and the tip touching the residues close to the interior diiron center (Figs. 1A, 2A ). Docking studies of COH20 suggested several binding poses; however, the flat conformation had the best docking score and consistency with the experimental results. In this conformation, the pharmacophore group 3, 4-dihydroxyl of COH20 formed hydrogen bonds with Tyr323 and Met350, while the binding group extended outside the pocket, implying that structural hindrance between it, and the charged surface residues Asp271 and Glu334 prevented deep docking into the pocket. This is consistent with our SAR analysis showing that the bulkiness and hydrophobicity of the binding group attenuated inhibition. Other important features are that Tyr323 is the only pocket 5 tyrosine residue with a hydroxyl group of redox potential, and that the Arg330 at the edge of the pocket, between Tyr323 and Asp271, forms multiple hydrogen bonds with COH20 and caps the pocket.
Site-directed mutagenesis study
We validated pocket 5 and the ligand binding mode by site-directed mutagenesis of twelve pocket 5 residues and two C-loop residues (Table 1) . A non-pocket mutant E291A served as internal control. Six pocket residue mutations significantly altered or abolished RNR activity, indicating that they are critical to enzyme function and stability. We tested the effect in vitro of 10 µM COH20 on wild-type protein and six mutants; recombinant wild-type hRNR activity was inhibited by 40%, and RRM1/RRM2-R330A activity by over 75%, equating to a 40% increased sensitivity (Fig. 2B) . We found similar results with G233V and D271A mutants, implicating these residues in ligand binding. In contrast, for both the S263L and E334R mutations inhibition was attenuated, indicating the positive roles for these residues in the inhibitor binding. The 40% increased COH20 inhibition by the C-terminal mutant M372F indicated that Table S1 ).
Structure-based optimization of the lead compounds
We conducted another round of lead optimization based on structural features of the ligand binding pocket and the proposed flat conformation ligand binding mode, in which there is a space between COH20 and Gly233-hRRM2 of the αE-helix deep in the pocket ( Fig. 2A) . First we tested whether replacement of Gly233 with valine, which is longer and bulkier, could provide extra protein-ligand interactions. The G223V mutant retained most of the enzyme activity (80% of wild-type, Table 1 and Fig.   S3B ), however, 10 µM COH20 markedly decreased the in vitro relative activity to 10% for G233V vs 60% for wild-type protein, Fig. 2B ). The point mutation contributed 50% activity loss, indicating Gly233
is involved in the inhibition and Val233 significantly contributes to this as predicted. By NMR analysis, G233V caused significant line broadening of COH20 (Fig. S2E) , demonstrating the mutation changed the ligand-protein interaction exchange rates or binding kinetics. The sum of the results suggested that the inhibitory activity of COH20 could be optimized by addition of a side-chain. We synthesized and tested compounds with a variety of side chains.(33) The most effective was COH29 (Fig. 1E), N-(4-(3,4- dihydroxyphenyl)-5-phenylthiazol-2-yl)-3,4-dihydroxybenzamide, which had an extra phenyl ring structure from the linking aminothiazole ring of COH20 (Fig. 1D) . COH29 inhibited recombinant RRM1/RRM2 activity in vitro with an IC 50 of 16 µM. Docking of COH29 to hRRM2 showed a similar binding mode in pocket 5 as COH20 with the extra phenyl ring touching Gly233 as predicted (Fig. S3A ).
Mutagenesis studies confirmed residues Asp271, Tyr323, Phe326, Val327, and Met350 are involved in COH29 binding.
COH29 binds RRM2, interfering with RRM1-RRM2 interactions
We used surface plasmon resonance biosensor experiments to study real-time COH29 -hRRM2 interaction. There was a dose-dependent interaction between immobilized full-length hRRM2 and COH29, reflected in the initial rising portion of the sensorgram (Fig. 3A) . Removal of 41 C-terminal amino acids from hRRM2 greatly decreased COH29 binding (Fig. 3B) , showing the C-terminal tail is important. Next, binding of RRM1 to immobilized RRM2 was confirmed over a range of concentrations of RRM1 (0 -1 μM) (Fig. 3C) . When a fixed concentration of RRM1 (0.5 μM) in the presence of escalating COH29 concentrations (0 -50 μM) was tested with immobilized RRM2, COH29 interfered with RRM1-RRM2 binding in a dose-dependent manner (Fig. 3D) . COH29 enhanced RRM1-RRM2 interaction at low dose (12.5 μM) but disrupted the complex at higher dose (> 25μM).
COH29 inhibits intracellular hRNR activity
We showed that in cultured KB human cancer cells endogenously expressed RNR activity was approximately 50% decreased after 24 h incubation with 10 µM COH29 (Fig. 4A) , whereas hRRM2
protein level was unaffected in both KB and TOV-112D cells (Fig. 4B) . We compared the efficacy of COH29 to HU and gemcitabine (Gem) in KB cells. The IC 50 of COH29 is 8 µM, similar to that of Gem (9 µM) but dramatically lower than that of HU (180 µM) in cell proliferation assays (Fig. 4C) . Consistent with this, real-time KB cell growth was essentially halted by addition of 20 µM COH29 at 24 h, whereas cell growth continued after addition of either 20 µM Gem or 1 mM HU for approximately 60-70 hours (Fig. 4D) .
Depletion of dNTP pools is a consequence of RNR inhibition. We assayed the levels of dATP, dCTP and dGTP at 4, 8, and 24 hours of exposure of MOLT-4 cells to 10 μM COH29. The dNTP levels were differentially affected, but by 24 h all pools were greatly decreased ( Fig. 4E-G ). Unbalanced dNTP pools should activate the replication checkpoint and result in S phase-arrest. Indeed, KB cells were arrested at S-phase after 48 h of COH29 treatment (Fig. S4, bottom) , and underwent apoptosis (Fig. S4, top and middle).
COH29 and COH20 cytotoxicity in human cancer cells
The cytotoxicity of COH20 and COH29 was examined with the NCI broad panel of 60 human cancer cell lines. Impressive inhibition of most of the cancer cell lines was observed in in vitro MTT cytotoxicity assays, with ovarian cancer and leukemia cells being the most sensitive to 10 µM COH29 and to COH20 (Fig. S5) . COH29 is more effective than COH20 in most of the cell lines. Importantly, COH29 was 10-fold less toxic to human normal fibroblast cells (NHDF) and human umbilical vein endothelial (HUVEC) cells (Fig. 5A , 5B) than to the KB cancer cell line (IC 50 of 82 µM in NHDF).
COH29 overcomes resistance to Gem and HU
We used clones of KB resistant to HU (KB-HURs), and Gem (KB-Gem) as model systems to test COH29 in drug-resistant cells. COH29 retained activity in HU and Gem resistant cells in 72 h toxicity assays, with an IC 50 of 8 µM in KB-HURs and KB-Gem (Fig. 5C, 5D ). In contrast, HU was far less cytotoxic in the KBHURs line than in the parental line (IC 50 320 µM vs 180 µM, respectively). As expected, gemcitabine was far less active in the resistant clone than in the KB parental line, as shown by the IC 50 increasing from 9 µM to 1000 µM. The real-time growth curves for KBHURs in the presence of HU (2-50 mM) and COH29 (2-250 µM) clearly showed that the HU-resistant cells remained sensitive to COH29 (Fig. S6A) . Real-time growth curves for KB-Gem in the presence of Gem (20-500 μM) and COH29 (2-250 µM) similarly showed that COH29 cytotoxic activity is strong and is unaffected by Gem resistance (Fig. S6B) .
In vivo tumor growth inhibition and activity
We investigated the antitumor activity of COH29 using murine tumor xenograft models of MOLT-4 leukemia cells or TOV11LD ovarian cancer cells, which were implanted and allowed to grow until the tumor was measurable at the subcutaneous site before oral administration of COH29 was begun. COH29 resulted in a dose-dependent inhibition of MOLT-4 tumor xenograft growth with twice-daily oral dosing at 50 mg/kg and 100 mg/kg, which was pronounced by Day 12 of treatment (Fig. 6A) . Similarly, 7 days of treatment of mice bearing TOV11D xenografts with 200, 300, or 400 mg/kg/day COH29 resulted in a dose-dependent inhibition of tumor xenograft growth (Fig. 6B) . Tumor growth was significantly inhibited compared with the control group.
Preliminary investigation of the pharmacokinetics (PK) of intravenous vs oral formulations of COH29
showed that following PO administration in female Balb/c nude mice at a dose 800 mg/kg in 30% solutol, COH29 was quickly absorbed with a mean T max of 0.5 h, and was slowly eliminated with a mean terminal elimination t 1/2 of 10h (Fig. 6C) . The COH29 peak plasma concentration was 10 µM. COH29 decreased to approximately 0.2 µM by 24 h. Compared to the intravenous route of administration, the oral bioavailability of COH29 was determined to be 25%. COH29 was also well tolerated in mice, with no appreciable side effects observed up to a daily dose of 500 mg/kg. RNR activity in extracts of the MOLT-4 tumor xenografts shown in Fig. 6A was dramatically lower in the tumors from mice that had been treated with COH29 for 12 days (Fig. 6D) , confirming that COH29 inhibits its target in vivo. Consistent with decreased RNR activity, intratumoral dNTP pools were also decreased in xenografts from mice treated with COH29 vs. control (Fig. 6E-G) .
DISCUSSION
Using a structure-and mechanism-based approach we designed and developed a novel class of RNR inhibitors with potential clinical utility, having better drug resistance and cytotoxicity profiles than the clinically established agents. COH29 inhibits RNR activity in vitro in the micromolar range and is active in tissue culture and human tumor xenografts in mice. Using the NCI panel of 60 cancer cell lines we established that COH29 was broadly active, with ovarian cancer and leukemic cell lines being particularly susceptible. In contrast, cultured non-malignant human cells -dermal fibroblasts and HUVECs -were 10 times less sensitive to COH29 in viability assays, an encouraging indication that this compound would be relatively non-toxic in vivo where normal cell replication is lower than in cell culture. COH29 did not affect the expression of RRM2 in vitro, and we conclude that in vitro inhibition of RNR is via a direct effect on the enzyme activity and not by regulation of protein expression. Further, in cell cultures and in tumor xenografts we consistently detected the primary biological consequence of RNR inhibitionperturbation of dNTP pools. Consistent with inhibition of RNR and its established role of catalyzing the rate-limiting step in dNTP synthesis and therefore DNA synthesis (1, 2) we observed S-phase arrest in cell cultures treated with COH29.
Our successful development of COH29 is based on the novel binding pocket we identified (33) , which is located in a position close to the R1-R2 interface that makes it potentially capable of multiple functional and biologically relevant effects. Notably, at the pocket apex the helix E residues Gly233 and Phe236 are close to the interior diiron center; near the surface residues Asp271 R330 and Glu334 form a charged cluster opposite the hydrophobic moiety capable of specific aromatic interactions formed by residues Phe236, Phe240, Tyr323, and Phe326. The C-loop of hRRM2 encloses the pocket close to the RRM2-RRM1 interface. Potential inhibitory ligand modes of action include: interference with RRM1-RRM2 holoenzyme assembly and radical transfer, disturbance of the iron center, and blocking the oxygen passage channel. The surface plasmon resonance biosensor experiments confirmed that COH29 binds hRRM2, involving the hRRM2 C-terminal tail; more importantly, COH29 interferes with RRM1-RRM2 interactions, therefore disrupting holoenzyme complex formation. This study suggested a new RNR inhibition mechanism acting via interference with the RRM2 side of the RRM1-RRM2 interface.
Currently many groups are investigating several proposed mechanisms for RNR inhibition (34) (35) (36) .
Recently Gräslund's group proposed a binding pocket in a similar position to our pocket 5 in a molecular docking study of metal complexes of Triapine (3-AP) using a mouse RRM2 model (36) . They found two binding pockets because of the smaller size of their ligand, which also docked deeper into the iron site. A mechanism of labilization of the RRM2 diferric center by 3-AP and subsequent 3-AP action as an iron chelator was proposed. In line with their finding, we noted that mutations around the tip of pocket 5 significantly reduced the enzyme activity (F236A, G267V; Table 1 , Fig. S3B ), supporting disturbance of the iron center by 3-AP. We note that clinically 3-AP produced iron-chelation-related toxicities (19) that we predict COH29 will avoid as our models indicate that it does not bind as deep into the iron site.
COH29 is a potential radical quencher due to the 3, 4-dihydroxybenzene group, which has a reduction potential lower than tyrosine (37) . In a similar compound, 3, 4-dihydroxyphenylalanine (DOPA), the 3, 4-dihydroxyl group was readily oxidized and served as a radical trap (37) . Substitution of the C-terminal residue in the PCET pathway, Tyr356 in E. coli RRM2 (Tyr369 in hRRM2), with DOPA resulted in the formation of a DOPA radical intercepting the radical transfer pathway and diminishing RNR activity (38, 39) . COH29 binds close to the C-terminal loop and helix, and it is possible that it inhibited the enzyme activity by ligand-radical interception. Therefore, the ligands of the novel binding pocket could have CAN-13-1094 multiple modes of inhibition of RNR activity, which makes the pocket an important and effective target for therapeutic agent design. The multiple functional features of the pocket and the structural features of COH29 may allow for multiple modalities of interference with RRM2 functions, in turn resulting in the high efficacy of the inhibitor.
We also compared the activity of COH29 to the clinically established RNR inhibitors HU and gemcitabine, neither of which are specific RNR inhibitors (17) , in tumor cell cultures. In addition to offtarget effects, acquired resistance to these drugs has limited their clinical effectiveness. For nearly two decades we have used the KB epithelioid cell line to study RNR and have derived HU and gemcitabineresistant clones (12, 13) . In addition to showing that in KB cells COH29 has similar antiproliferative activity to Gem, and is over 20-fold more active than HU, we showed that COH29 activity was unaffected in the drug resistant KBHURs and KB-Gem clones. This indicates that COH29 bypasses the mechanisms by which resistance to HU and gemcitabine develop. This is most likely due to the differences in the mechanisms of action. Unlike COH29, gemcitabine binds the RRM1 subunit, while HU interaction with the RRM2 subunit is less specific and does not involve pocket 5. 
TABLES
